ProfileGDS5678 / 1449019_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 34% 35% 35% 38% 45% 32% 33% 45% 35% 54% 35% 36% 35% 35% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8066734
GSM967853U87-EV human glioblastoma xenograft - Control 22.8027935
GSM967854U87-EV human glioblastoma xenograft - Control 32.8059735
GSM967855U87-EV human glioblastoma xenograft - Control 42.8242438
GSM967856U87-EV human glioblastoma xenograft - Control 53.0038545
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.81632
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7929733
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0382745
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7814835
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3352554
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7954435
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.798336
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8075735
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8001435